Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Leuprolide monotherapy Variant #01 | — | R 253 833 | 90d | — | — | ~2 | ~R 507 665 PFS proxy · indirect | 2 |
Bicalutamide and Goserelin Variant #01 | — | R 8 166 | 84d | — | — | ~1 | ~R 8 166 PFS proxy · indirect | 2 |
Degarelix monotherapy Variant #04 | — | R 4 219 | 84d | — | — | ~2 | ~R 5 907 indirect | — |
Flutamide and Goserelin Variant #01 | — | R 3 653 | 28d | — | ~69.6 mo | ~3 | ~R 10 960 PFS proxy · indirect | 1 |
ADT Variant #01 Partial | — | — | — | — | — | 1 | — | 1 |
5 of 5 regimens shown